Adial Pharmaceuticals appoints Cary Claiborne as COO effective Dec 6, 2021

ADIAL PHARMACEUTICALS, INC.

Cary Claiborne appointed COO; continues to serve on Board of Directors.
Employment agreement: $304,000 base salary, 25% target bonus, three-year term.
Awarded option to purchase 130,000 shares at $2.77, vesting monthly over 36 months.
Joseph Truluck resigns as COO but remains CFO of the company.
Press release issued December 8, 2021 announcing the appointment.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Cary Claiborne

Chief Operating Officer

ADIL · ADIAL PHARMACEUTICALS, INC.

Effective: 2021-12-06
Filed: December 9, 2021, 6:59 PM ET

On December 6, 2021, Adial Pharmaceuticals, Inc. (the “Company”) appointed Cary Claiborne as the Company’s Chief Operating Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Cary Claiborne was appointed as Chief Operating Officer at ADIAL PHARMACEUTICALS, INC..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On December 6, 2021, Adial Pharmaceuticals, Inc. (the “Company”) appointed Cary Claiborne as the Company’s Chief Operating Officer.

View on SEC.gov

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-21-064319

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.